title: Effect of systemic insulin and angiotensin II receptor subtype-1 antagonist on endothelin-1 receptor subtype(s) regulation and binding in diabetic rat heart.
abstract: This study reports on the regulation and remodeling role of endothelin-1 (ET-1) and its receptor subtypes, ET(A)-Rs/ET(B)-Rs, at the coronary endothelium (CE) and cardiomyocyte (CM) sites. It is carried out in normal and normotensive rats with streptozotocin-induced diabetes mellitus receiving different treatment modalities. Normal rats were divided into two groups, namely a placebo (N) and a losartan-treated (NL), and diabetic rats into four groups receiving placebo (D), insulin-treated (DI), losartan-treated (DL), and insulin/losartan-treated (DIL) respectively. Binding kinetics of ET-1 to ET(A)-Rs/ET(B)-Rs on CE and CMs were assessed in the above groups to try to explain the effect of therapeutic doses of an angiotensin II receptor subtype-1 blocker on the dynamics of this ligand and its receptor in insulin supplemented diabetic animals. Each group was divided into two subgroups: CHAPS-untreated and CHAPS-treated rat hearts perfused with [125I]ET-1 to respectively estimate ET-1 binding affinity (tau = 1/k-n) to its receptor subtype(s) on CE and CMs using mathematical modeling describing a 1:1 reversible binding stoichiometry. Heart perfusion results revealed that insulin treatment significantly decreased tau on CE but not on CMs in diabetic rats. In diabetics treated with losartan, an increase in tau value on CE but not on CMs was noted. Cotreatment of diabetic rats with insulin and losartan normalized tau on CE but decreased it on CMs. Western blot, using snap-frozen heart tissues, revealed increase in ET(A)-R density in all diabetic groups. However, significant decrease in ET(B)-R density was observed in all groups compared to the normal, and was reconfirmed by immunohistochemical analysis. In conclusion, coadministration of insulin and losartan in nonhypertensive animals suffering from diabetes type 1 may offer new cardiac protection benefits by improving coronary blood flow and cardiomyocyte contractility through modulating ET-1 receptor subtypes density and affinity at CE and CM sites.
authors.affiliation: Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: Chehade N
authors.initials: CN
authors.lastname: Karam
authors.forename: Nuha
authors.initials: N
authors.lastname: Nuwayri-Salti
authors.forename: Julnar A
authors.initials: JA
authors.lastname: Usta
authors.forename: Darine S
authors.initials: DS
authors.lastname: Zwainy
authors.forename: Roy E
authors.initials: RE
authors.lastname: Abrahamian
authors.forename: Wael A
authors.initials: WA
authors.lastname: Al Jaroudi
authors.forename: Malek J
authors.initials: MJ
authors.lastname: Baasisri
authors.forename: Samer M
authors.initials: SM
authors.lastname: Abdallah
authors.forename: Khalil M
authors.initials: KM
authors.lastname: Bitar
authors.forename: Anwar B
authors.initials: AB
authors.lastname: Bikhazi
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019332:Endothelin-1 / Q000378:metabolism / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D008954:Models, Biological; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D010477:Perfusion; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D019332:Endothelin-1; D007004:Hypoglycemic Agents; D007328:Insulin; D044022:Receptor, Endothelin A